Products
Data Sets
Integrations
Services
FUNDRAISING NEWS | December 10, 2024
Venture capital firm Dimension Capital announced the launch of its second fund targeting startups at the intersection of life sciences and technology, seeking to raise $500M for the new fund.
Dimension Capital II aims to continue on the success of the firm’s oversubscribed $350M first fund, which capitalized on emerging investor interest in the life sciences sector. For Dimension II, the firm has expanded its remit to include robotics companies, machine-learning-focused firms, and early stage and wholly-owned clinical trials.
Since its inception in 2022, the firm has invested in 28 biotech companies, including Chai Discovery, a startup building an open-source AI model for drug discovery, and Enverda Biosciences, a biotech company leveraging AI to discover new medicines from natural compounds.
Written By: Dakota
Gaming and Digital Entertainment VC Transcend to Launch Third Seed Fund
January 21, 2025
Mesa Lane Targets $300M for Emerging Managers Fund
January 02, 2025
Project A Targets $315.2M with Fourth Early-stage Euro Tech Fund
December 17, 2024
Biotech VC Dimension Launches $500M Second Fund
December 10, 2024
Report: Carlyle-backed VC Abingworth Launches $1.5B Clinical Trials Fund
December 02, 2024
925 West Lancaster Ave
Suite 220
Bryn Mawr, PA 19010
Tel: (610) 642-1481
© Dakota 2025 | Terms of Use | Privacy Policy
